[go: up one dir, main page]

ZA200806386B - Thiazole compounds as protein kinase B (PKB) Inhibitors - Google Patents

Thiazole compounds as protein kinase B (PKB) Inhibitors

Info

Publication number
ZA200806386B
ZA200806386B ZA200806386A ZA200806386A ZA200806386B ZA 200806386 B ZA200806386 B ZA 200806386B ZA 200806386 A ZA200806386 A ZA 200806386A ZA 200806386 A ZA200806386 A ZA 200806386A ZA 200806386 B ZA200806386 B ZA 200806386B
Authority
ZA
South Africa
Prior art keywords
pkb
inhibitors
protein kinase
thiazole compounds
thiazole
Prior art date
Application number
ZA200806386A
Other languages
English (en)
Inventor
Zeng Qingping
John G Allen
Matthew P Bourbeau
Dominguez Celia
Christopher H Fotsch
Hah Nianhe
Hong Fang-Tsao
Huang Xin
Matthew R Lee
Li Aiwen
Liu Qingyian
James T Rider
Tadesse Seifu
Andrew S Tasker
Vellarkad N Viswanadhan
Wang Xianghong
Kurt E Weiler
George E Wohlhieter
Yao Guomin
Yuan Chester Chenguang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA200806386B publication Critical patent/ZA200806386B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200806386A 2006-01-18 2008-07-23 Thiazole compounds as protein kinase B (PKB) Inhibitors ZA200806386B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954606P 2006-01-18 2006-01-18

Publications (1)

Publication Number Publication Date
ZA200806386B true ZA200806386B (en) 2009-11-25

Family

ID=38180602

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200806386A ZA200806386B (en) 2006-01-18 2008-07-23 Thiazole compounds as protein kinase B (PKB) Inhibitors

Country Status (21)

Country Link
US (2) US7514566B2 (xx)
EP (1) EP1981884B1 (xx)
JP (1) JP5199885B2 (xx)
KR (1) KR20080091369A (xx)
CN (1) CN101421265A (xx)
AR (1) AR059064A1 (xx)
AU (1) AU2007207743B2 (xx)
BR (1) BRPI0706621A2 (xx)
CA (1) CA2636077C (xx)
CR (1) CR10211A (xx)
EA (1) EA200801716A1 (xx)
ES (1) ES2389062T3 (xx)
IL (1) IL192751A0 (xx)
MY (1) MY149143A (xx)
NO (1) NO20083572L (xx)
PE (1) PE20071114A1 (xx)
TW (1) TW200738657A (xx)
UA (1) UA91895C2 (xx)
UY (1) UY30098A1 (xx)
WO (1) WO2007084391A2 (xx)
ZA (1) ZA200806386B (xx)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2400689T3 (es) * 2004-10-18 2013-04-11 Amgen, Inc Compuestos de tiadiazol y métodos de uso
ES2389062T3 (es) * 2006-01-18 2012-10-22 Amgen, Inc Compuestos de tiazol como inhibidores de proteína cinasa B (PKB)
WO2008100456A2 (en) * 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
CA2692713A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
AU2008276512A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
UA103319C2 (xx) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Сполуки бензенсульфонамідтіазолу та -оксазолу$соединения бензенсульфонамидтиазола и -оксазола
EP2303017A4 (en) * 2008-06-26 2011-06-15 Glaxosmithkline Llc HAMMER OF ACT ACTIVITY
US20120040974A1 (en) * 2008-08-18 2012-02-16 Yale University Mif modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
LT3135672T (lt) * 2008-10-10 2020-05-25 Vm Discovery, Inc. Kompozicijos ir būdai skirti gydyti alkoholio vartojimo sutrikimus, skausmą ir kitas ligas
NZ593537A (en) * 2008-12-19 2013-07-26 Genentech Inc Isoquinoline derivatives and methods of use
US20110263647A1 (en) * 2009-01-15 2011-10-27 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
EA022982B1 (ru) * 2009-10-08 2016-04-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Комбинация для лечения рака или предраковых синдромов
WO2011044415A1 (en) * 2009-10-08 2011-04-14 Glaxosmithkline Llc Combination
CN102665720A (zh) * 2009-10-12 2012-09-12 葛兰素史密斯克莱有限责任公司 组合
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
CA2779574C (en) 2009-11-05 2018-12-18 Rhizen Pharmaceuticals S.A. Novel kinase modulators
KR20130038224A (ko) * 2010-03-15 2013-04-17 가부시키가이샤 구라레 티에노피리딘 유도체 및 그 제조 방법, 그리고 그것을 사용한 유기 반도체 디바이스
JP5578705B2 (ja) * 2010-03-29 2014-08-27 公益財団法人相模中央化学研究所 (アリール)ジフルオロ酢酸エステル誘導体及びその製造方法
ES2454567T3 (es) * 2010-04-16 2014-04-10 Abbvie Inc. Inhibidores de quinasas ftalazin-(2h)-ona
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2011133733A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
AP4075A (en) 2011-05-04 2017-03-23 Rhizen Pharmaceuticals S A Novel compounds as modulators of protein kinases
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
CN103304468A (zh) * 2012-03-13 2013-09-18 华东师范大学 一种氧化吲哚的一锅法串联合成方法
EP2832731A4 (en) * 2012-03-27 2015-08-19 Shionogi & Co AROMATIC HETEROCYCLIC CHAIN 5-CORE DERIVED DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
DK3260455T3 (da) 2012-07-04 2019-06-11 Rhizen Pharmaceuticals S A Selektive pi3k delta-hæmmere
JP6417338B2 (ja) 2013-02-19 2018-11-07 アムジエン・インコーポレーテツド 癌の治療のためのmdm2阻害剤としてのシス−モルホリノン及び他の化合物
SG10201806965XA (en) * 2013-03-13 2018-09-27 Boston Biomedical Inc 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
TN2016000176A1 (en) 2013-11-11 2017-10-06 Amgen Inc Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
ES2789331T3 (es) * 2015-03-02 2020-10-26 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
CA3015893C (en) * 2016-03-10 2021-11-09 Astrazeneca Ab Novel inhibitors of phosphatidylinositol 3-kinase gamma
WO2018183964A1 (en) 2017-03-30 2018-10-04 Genentech, Inc. Isoquinolines as inhibitors of hpk1
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
UY37870A (es) 2017-09-08 2019-03-29 Amgen Inc Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
JP7012152B2 (ja) 2017-10-05 2022-02-10 フルクラム セラピューティクス,インコーポレイテッド Fshdの治療のためにdux4および下流遺伝子発現を低減するp38キナーゼ阻害剤
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
AU2019336588B2 (en) 2018-06-12 2022-07-28 Amgen Inc. KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
KR20250171404A (ko) 2018-08-31 2025-12-08 암젠 인크 Mdm2 억제제의 제조 방법
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CR20210665A (es) 2019-05-21 2022-01-25 Amgen Inc Formas en estado sólido
CN114391012B (zh) * 2019-08-02 2025-10-31 美国安进公司 作为kif18a抑制剂的吡啶衍生物
US20240139193A1 (en) 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021126816A1 (en) 2019-12-16 2021-06-24 Amgen Inc. Dosing regimen of a kras g12c inhibitor
US12178902B1 (en) 2020-01-12 2024-12-31 University Of Southern California Methods and compositions for fluid drainage by Piezo ion channel activation
CN111603466B (zh) * 2020-06-29 2022-07-22 江南大学 一种乙酮类化合物在制备治疗肿瘤药物中的应用
CN114014787B (zh) * 2022-01-10 2022-03-22 苏州开元民生科技股份有限公司 一种制备(2s,3r)-对甲砜基苯丝氨酸乙酯的不对称合成方法
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591600A (en) * 1969-07-07 1971-07-06 Stauffer Chemical Co 2-aminothiazole phosphates and phosphonates
GB1435139A (en) * 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
JPS5239827B2 (xx) 1973-11-08 1977-10-07
US4086239A (en) * 1977-07-01 1978-04-25 Stauffer Chemical Company Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods
DK150068C (da) 1978-06-02 1987-06-29 Pfizer Analogifremgangsmaade til fremstilling af aminothiazoler
US4297365A (en) * 1978-08-04 1981-10-27 Ciba-Geigy Corporation Benzimidazoles and pharmaceutical preparations containing such compounds
US4451471A (en) * 1981-03-18 1984-05-29 Ciba-Geigy Corporation Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same
FR2511375A1 (fr) * 1981-08-17 1983-02-18 Rhone Poulenc Sante Nouveaux derives de la cephalosporine, leur preparation et les medicaments qui les contiennent
DE3630732A1 (de) * 1986-09-10 1988-03-17 Bayer Ag 2-cyano-2-alkoximino-acetamide
US5232921A (en) * 1987-03-12 1993-08-03 Sanofi Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions
JPH0753666B2 (ja) 1987-09-14 1995-06-07 久光製薬株式会社 置換ジフェニルチアゾール誘導体からなる抗炎症剤
FR2636628B1 (fr) * 1988-08-25 1990-12-28 Sanofi Sa Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant
US5302608A (en) * 1988-11-18 1994-04-12 Takeda Chemical Industries, Ltd. Age formation inhibitors
US5145860A (en) * 1989-01-05 1992-09-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds and pharmaceutical composition comprising the same
US5550138A (en) * 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
AU689972B2 (en) * 1994-11-29 1998-04-09 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
FR2735777B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
ES2237919T4 (es) 1998-06-18 2007-05-01 Bristol-Myers Squibb Company Inhibidores aminotiazol sustituidos con carbono de quinasas dependientes de ciclina.
US6407124B1 (en) * 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
AU3487500A (en) 1999-02-08 2000-08-25 Lion Bioscience Ag Thiazole derivatives and combinatorial libraries thereof
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001114690A (ja) * 1999-08-06 2001-04-24 Takeda Chem Ind Ltd p38MAPキナーゼ阻害剤
CA2381215A1 (en) * 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
US7495018B2 (en) * 2000-03-30 2009-02-24 Takeda Pharmaceutical Company Limited Substituted 1,3-thiazole compounds, their production and use
AU2001249670A1 (en) * 2000-04-03 2001-10-15 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
US7074934B2 (en) * 2000-06-13 2006-07-11 Tularik Limited Serine protease inhibitors
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
JP4689801B2 (ja) 2000-08-09 2011-05-25 ケミプロ化成株式会社 アミノチアゾール誘導体の製造方法
JP2002053566A (ja) 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
GB0114185D0 (en) * 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
AR032653A1 (es) * 2001-02-09 2003-11-19 Telik Inc Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
ATE315555T1 (de) * 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
US20050080113A1 (en) * 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
ATE349443T1 (de) * 2001-09-28 2007-01-15 Cyclacel Ltd N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n- phenylamine als antiproliferative verbindungen
GB0123589D0 (en) * 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
US20050004134A1 (en) * 2001-11-08 2005-01-06 Hideo Tsutsumi Thiazole derivative and pharmaceutical use thereof
JP2005526720A (ja) 2002-02-13 2005-09-08 ファーマジーン ラボラトリーズ リミテッド 5−ht2b受容体アンタゴニスト
TWI314928B (en) * 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
JP2005526732A (ja) * 2002-02-28 2005-09-08 エフ.ホフマン−ラ ロシュ アーゲー Npy受容体拮抗剤としてのチアゾール誘導体
US20040053948A1 (en) * 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
OA12937A (en) * 2002-10-09 2006-10-13 Pfizer Prod Inc Thiazole compounds for the treatment of neurodegenerative disorders.
TW200416221A (en) 2002-10-30 2004-09-01 Vertex Pharma Compositions useful as inhibitors of ROCK and other protein kinases
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
FR2850380B1 (fr) * 2003-01-23 2006-07-07 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd 7員複素環誘導体
TW200519106A (en) * 2003-05-02 2005-06-16 Novartis Ag Organic compounds
JP2007512230A (ja) * 2003-08-20 2007-05-17 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用な(4−アミノ−1,2,5−オキサジアゾール−4−イル)−ヘテロ芳香族化合物
US7973169B2 (en) * 2003-09-06 2011-07-05 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
EA012328B1 (ru) 2004-01-12 2009-08-28 Лаборатуар Сероно Са Производные тиазола и их применение
CA2551142A1 (fr) * 2004-01-16 2005-08-11 Sanofi-Aventis Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
ATE517098T1 (de) * 2004-01-16 2011-08-15 Sanofi Sa Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren
WO2005085227A1 (en) * 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
EP1730119B1 (en) 2004-03-23 2008-06-25 Pfizer Products Incorporated Imidazole compounds for the treatment of neurodegenerative disorders
US7470701B2 (en) * 2004-03-30 2008-12-30 Novartis Vaccines And Diagnostics, Inc. Substituted 2,5-heterocyclic derivatives
EP1740609A2 (en) * 2004-04-27 2007-01-10 Research Development Foundation Antagonism of tgf-beta superfamily receptor signaling
US7893020B2 (en) * 2004-05-21 2011-02-22 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
SG155222A1 (en) 2004-08-13 2009-09-30 Genentech Inc Thiazole based inhibitors of atp-utilizing enzymes
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
ES2400689T3 (es) * 2004-10-18 2013-04-11 Amgen, Inc Compuestos de tiadiazol y métodos de uso
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
EP1854793A4 (en) * 2005-02-28 2011-01-26 Japan Tobacco Inc NEW AMINOPYRIDEIN COMPOUND WITH SYK-HEMDERING EFFECT
CA2612338C (en) * 2005-06-17 2015-02-03 Apogee Biotechnology Corporation Sphingosine kinase inhibitors
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
US7871982B2 (en) 2005-12-09 2011-01-18 Meiji Seika Kaisha, Ltd. Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient
TW200730476A (en) 2005-12-12 2007-08-16 Genelabs Tech Inc N-(5-membered aromatic ring)-amido anti-viral compounds
ES2389062T3 (es) 2006-01-18 2012-10-22 Amgen, Inc Compuestos de tiazol como inhibidores de proteína cinasa B (PKB)
CN101370799B (zh) 2006-01-18 2012-09-05 霍夫曼-拉罗奇有限公司 作为mdm2抑制剂的顺-4,5-二芳基-2-杂环-咪唑啉
PE20071320A1 (es) 2006-01-18 2007-12-29 Schering Corp Moduladores de receptores cannabinoides
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
ES2389062T3 (es) 2012-10-22
KR20080091369A (ko) 2008-10-10
BRPI0706621A2 (pt) 2011-04-05
JP2009525960A (ja) 2009-07-16
US20090270445A1 (en) 2009-10-29
WO2007084391A2 (en) 2007-07-26
UA91895C2 (xx) 2010-09-10
CA2636077C (en) 2012-01-03
WO2007084391A3 (en) 2008-03-20
CR10211A (es) 2008-10-03
US20070173506A1 (en) 2007-07-26
TW200738657A (en) 2007-10-16
CN101421265A (zh) 2009-04-29
AU2007207743B2 (en) 2010-07-08
NO20083572L (no) 2008-10-17
AU2007207743A1 (en) 2007-07-26
MY149143A (en) 2013-07-15
EP1981884A2 (en) 2008-10-22
US8084479B2 (en) 2011-12-27
CA2636077A1 (en) 2007-07-26
EA200801716A1 (ru) 2009-04-28
JP5199885B2 (ja) 2013-05-15
UY30098A1 (es) 2007-10-31
PE20071114A1 (es) 2008-01-10
EP1981884B1 (en) 2012-06-13
AR059064A1 (es) 2008-03-12
IL192751A0 (en) 2009-02-11
US7514566B2 (en) 2009-04-07

Similar Documents

Publication Publication Date Title
IL192751A0 (en) Thiazole compounds as protein kinase b (pkb) inhibitors
HUS1500049I1 (hu) Protein kináz inhibitor vegyületek és készítmények
IL230972A0 (en) Compounds and preparations as protein kinase inhibitors
IL197724A0 (en) Compounds and compositions as protein kinase inhibitors
IL198315A0 (en) Compounds and compositions as protein kinase inhibitors
PT2200436E (pt) Pirimidinilaminas substituídas como inibidoras da proteína quinase
IL206416A0 (en) Benzofuropyrimidinones as protein kinase inhibitors
SI2193133T1 (sl) Imidazolotiadiazoli za uporabo kot zaviralci protein-kinaze
PL1891066T3 (pl) Związki i kompozycje jako inhibitory kinazy białkowej
EP1841431A4 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
IL196554A0 (en) Heteroaryl derivatives as protein kinase inhibitors
PL2079727T3 (pl) Inhibitory kinazy
ZA200701281B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
SI1910348T1 (sl) Spojine benzotiazola in azabenzotiazola, uporabne kot kinazni inhibitorji
IL198487A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
IL198398A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
ZA200709269B (en) Protein kinase inhibitors
IL194699A0 (en) Tetrahydropteridines useful as inhibitors of protein kinases
EP2336123A4 (en) HETEROCYCLIC COMPOUND AS INHIBITOR OF PROTEIN KINASE
AU2007312310A1 (en) Phenylacetamides useful as protein kinase inhibitors
ZA200806871B (en) Dihydrodiazepines useful as inhibitors of protein kinases
IL194491A0 (en) Thiazolyldihydroindazole derivatives as protein kinase inhibitors
ZA200810573B (en) Substituted 3-cyanopyridines as protein kinase inhibitors
IL197981A0 (en) Kinase inhibitors
HK1126473A (en) Thiazole compounds as protein kinase b (pkb) inhibitors